Epidermal Growth Factor Receptor Mutation Status in Stage I Lung Adenocarcinoma with Different Image Patterns Kuo-Hsuan Hsu, MD, Kun-Chieh Chen, MD,

Slides:

Advertisements

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Advertisements

Association between the diagnosis-to-treatment interval and overall survival in Taiwanese patients with oral cavity squamous cell carcinoma Chun-Ta Liao,

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer Anne S. Tsao, MD, Xi Ming Tang, MD, PhD, Bradley Sabloff, MD,

Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer:

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations

Lung cancer screening with low-dose computed tomography: Experiences from a tertiary hospital in Taiwan Chih-Yu Chen, Chia-Hung Chen, Te-Chun Shen, Wen-Chien.

Quiz Page April 2011 American Journal of Kidney Diseases

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Surgical–pathologic factors affect long-term outcomes in stage IB (pT2 N0 M0) non– small cell lung cancer: A heterogeneous disease Chung-Ping Hsu, MD,

Y-L Chang, MD, C-T Wu, MD, Y-C Lee, MD, PhD

A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non–Small Cell Lung Cancer Patient Jong Sik Lee, MD, Jae Young Hur, PhD,

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

Histologic Evolution From Adenocarcinoma to Squamous Cell Carcinoma After Gefitinib Treatment Min-Shu Hsieh, MD, Jie-Yang Jhuang, MD, Syue-Fong Hua,

Resection of Mucinous Lung Adenocarcinoma Presenting with Intractable Bronchorrhea Motoshi Takao, MD, PhD, Takehiro Takagi, MD, Hitoshi Suzuki, MD, PhD,

Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer: A Brief Report Tsu-Hui Shiao, MD, Yih-Leong Chang, MD, Chong-Jen Yu, MD, PhD, Yeun-Chung.

Bob T. Li, M. B. B. S. , MPH, Dara S. Ross, MD, Dara L

Co-Overexpression of Cyclooxygenase-2 and Microsomal Prostaglandin E Synthase-1 Adversely Affects the Postoperative Survival in Non-small Cell Lung Cancer

Postchemoradiotherapy Pathologic Stage Classified by the American Joint Committee on the Cancer Staging System Predicts Prognosis of Patients with Locally.

EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR Shang-Gin Wu, MD, Yao-Wen Kuo, MD, Yih-Leong Chang,

MET and EGFR Mutations Identified in ALK-Rearranged Pulmonary Adenocarcinoma: Molecular Analysis of 25 ALK-Positive Cases Jennifer M. Boland, MD, Jin.

Spontaneous regression of a mediastinal thymoma

Percutaneous Computed Tomography-Guided Coaxial Core Biopsy for Small Pulmonary Lesions with Ground-Glass Attenuation Chia-Hung Lu, MD, FRCR, Cheng-Hsiang.

An Unusual Presentation of Malignant Pleural Mesothelioma

Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.

Prognostic Factors in Completely Resected Node-Negative Lung Adenocarcinoma of 3 cm or Smaller Jung-Jyh Hung, MD, PhD, Yi-Chen Yeh, MD, Yu-Chung Wu,

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer Anne S. Tsao, MD, Xi Ming Tang, MD, PhD, Bradley Sabloff, MD,

Surgical Treatment of a Giant Symptomatic Cardiac Lipoma

Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma Tzu-Hsiu Tsai,

Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer Registry Bing-Yen Wang, MD, Jing-Yang Huang, Ching-Yuan Cheng, MD, Ching-Hsiung Lin, MD,

Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion–Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations.

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations Chao-Hua.

Mark L. Kayton, MD, Mai He, MD, PhD, Maureen F. Zakowski, MD, Andre L

Loss of CRNN expression is associated with advanced tumor stage and poor survival in patients with esophageal squamous cell carcinoma Po-Kuei Hsu, MD,

Are There Imaging Characteristics Associated with Epidermal Growth Factor Receptor and KRAS Mutations in Patients with Adenocarcinoma of the Lung with.

The Prognostic Value of the Number of Negative Lymph Nodes in Esophageal Cancer Patients After Transthoracic Resection Po-Kuei Hsu, MD, Chien-Sheng Huang,

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis Bin-Chi Liao,

Do Complex Mutations of the Epidermal Growth Factor Receptor Gene Reflect Intratumoral Heterogeneity? Akito Hata, MD, Shiro Fujita, MD, PhD, Reiko Kaji,

Frequency of Lymph Node Metastasis According to the Size of Tumors in Resected Pulmonary Adenocarcinoma with a Size of 30 mm or Smaller Yangki Seok,

Thoracoscopic Lobectomy Produces Long-Term Survival Similar to That with Open Lobectomy in Cases of Non–Small Cell Lung Carcinoma: A Propensity-Matched.

Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemonaive, Advanced, Non- small Cell Lung Cancer Patients Aged 70 Years or Older Yuh-Min Chen,

ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers Samuel J. Klempner, MD, David W. Cohen, MD, Daniel.

MET Expression Plays Differing Roles in Non–Small-Cell Lung Cancer Patients with or without EGFR Mutation Ling Huang, MS, She-Juan An, PhD, Zhi-Hong.

Aglaya G. Iyevleva, MD, PhD Journal of Thoracic Oncology

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

S768I Mutation in EGFR in Patients with Lung Cancer

Is Thymectomy Necessary in Nonmyasthenic Patients with Early Thymoma?

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations

EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas

CT Features of Epidermal Growth Factor Receptor–Mutated Adenocarcinoma of the Lung: Comparison with Nonmutated Adenocarcinoma Mizue Hasegawa, MD, PhD,

Histological Subtypes of Lung Adenocarcinoma Have Differential 18F- Fluorodeoxyglucose Uptakes on the Positron Emission Tomography/Computed Tomography.

Shih-Chieh Chang, Cheng-Yu Chang, Chiung-Yu Chen, Chong-Jen Yu

Different Efficacies of Erlotinib and Gefitinib in Taiwanese Patients with Advanced Non- small Cell Lung Cancer: A Retrospective Multicenter Study Wen-Chien.

Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors

Two Generations of Light/Never-Smokers With Advanced Adenocarcinoma of the Lung with Durable Responses to Erlotinib Nathan A. Pennell, MD, PhD, Lihong.

The Relationship Between Air Pollution and Lung Cancer in Nonsmokers in Taiwan Chien-Hua Tseng, MD, Ben-Jei Tsuang, PhD, Chun-Ju Chiang, PhD, Kai-Chen.

EGFR Mutations in Squamous Cell Lung Cancer in Never-Smokers

PUB001 Advanced NSCLC Patients at the Extremes of Age in the Era of EGFR-TKIs Yu-Mu Chen, Chien-Hao Lai, Huang-Chih Chang, Tung-Ying Chao, Chia-Cheng.

Journal of Thoracic Oncology

Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small- Cell Lung Cancer Jih-Hsiang Lee, MD, Yu-Lin Lin, MD, Wei-Hsun Hsu,

Effect of Formalin Fixation on Tumor Size Determination in Stage I Non-Small Cell Lung Cancer Po-Kuei Hsu, MD, Hsu-Chih Huang, MD, Chih-Cheng Hsieh,

Good Response to Gefitinib in Lung Adenocarcinoma Harboring Coexisting EML4-ALK Fusion Gene and EGFR Mutation Yao-Wen Kuo, MD, Shang-Gin Wu, MD, Chao-Chi.

Patterns-of-Care for Thoracic Stereotactic Body Radiotherapy among Practicing Radiation Oncologists in the United States Megan E. Daly, MD, Julian R.

Epidermal Growth Factor Receptor Gene Mutation and Computed Tomographic Findings in Peripheral Pulmonary Adenocarcinoma Motoki Yano, MD, PhD, Hidefumi.

Postchemoradiotherapy Pathologic Stage Classified by the American Joint Committee on the Cancer Staging System Predicts Prognosis of Patients with Locally.

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Presentation transcript:

Epidermal Growth Factor Receptor Mutation Status in Stage I Lung Adenocarcinoma with Different Image Patterns Kuo-Hsuan Hsu, MD, Kun-Chieh Chen, MD, Tsung-Ying Yang, MD, Yi-Chen Yeh, MD, Teh-Ying Chou, MD, Hsuan-Yu Chen, PhD, Chi- Ren Tsai, PhD, Chih-Yi Chen, MD, Chung-Ping Hsu, MD, Jiun-Yi Hsia, MD, Cheng-Yen Chuang, MD, Ying-Huang Tsai, MD, Kuan-Yu Chen, MD, Ming-Shyan Huang, MD, Wu-Chou Su, MD, Yuh-Min Chen, MD, Chao A. Hsiung, PhD, Gee-Chen Chang, MD, Chien-Jen Chen, MD, Pan-Chyr Yang, MD Journal of Thoracic Oncology Volume 6, Issue 6, Pages 1066-1072 (June 2011) DOI: 10.1097/JTO.0b013e31821667b0 Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 A, Ground-glass opacity (GGO) ratio and epidermal growth factor receptor (EGFR) mutation status. B, Relationship of the GGO ratio, tumor size, and EGFR mutation status. Journal of Thoracic Oncology 2011 6, 1066-1072DOI: (10.1097/JTO.0b013e31821667b0) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Computed tomography (CT) image and histopathology of the tumor. A, CT scan with a part-solid pattern lung adenocarcinoma over right lung and (B) the low-power histopathology of the tumor in hematoxylin and eosin (H&E) stain (×20). There are invasive carcinoma cells in the central part of tumor (C) and in situ carcinoma cells arranged in a bronchioloalveolar pattern in the periphery (D). Both the central and peripheral tumor parts have the same EGFR mutation status, L858R. Journal of Thoracic Oncology 2011 6, 1066-1072DOI: (10.1097/JTO.0b013e31821667b0) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions